Congratulations Drs. Michael S. Okun and Adolfo Ramirez-Zamora on the publication of “Meta-analysis of Association between Newer Glucose-Lowering Drugs and Risk of Parkinson’s Disease,” which appears in the September issue of Movement Disorders, Clinical Practice.
The relationship between newer glucose-lowering (GLD) classes and the risk of Parkinson’s Disease (PD) is unclear. However, newer GLDs were significantly associated with a lower PD risk in a recent University of Florida-led study.
ABSTRACT
Background
The association between newer classes of glucose-lowering drugs (GLDs) and the risk of Parkinson’s disease (PD) remains unclear.
Objective
The aim was to examine the effect of newer GLDs on the risk of PD through a meta-analysis of randomized outcome trials.
Methods
The methods included randomized placebo-controlled outcome trials that reported PD events associated with three newer classes of GLDs (ie, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium-glucose co-transporter-2 inhibitors) in participants with or without type 2 diabetes. The pooled odds ratio (OR) and 95% confidence interval (CI) were estimated using Peto’s method.
Results
The study included 24 trials involving 33 PD cases among 185,305 participants during a median follow-up of 2.2 years. Newer GLDs were significantly associated with a lower PD risk (OR: 0.50; 95% CI: 0.25–0.98) than placebo.
Conclusion
Newer GLDs may possibly be associated with a decreased risk of PD; however, larger datasets are required to confirm or refute this notion.